# About TB-500 | An Independent Research Digest

> About this TB-500 research digest: an independent editorial project that summarizes the peer-reviewed thymosin beta-4 literature. Not a clinic, not a pharmacy, not a vendor.

What this site is, what it is not, and the one rule it holds to: state what the literature shows, and the gaps, with equal precision.

## What this site is

Pharmacy TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'pharmacy' in the name is editorial framing — a position this publisher occupies relative to the literature and the access landscape, the way a trade desk reads a market. It is not a claim that this site is a pharmacy, fills prescriptions, or supplies any substance. There is no counter here, and nothing on this site is dispensed or for sale.

## How we read the evidence

TB-500 is, by our reading, the most evidence-fraught compound we cover, and the editorial method follows from that. The heptapeptide sold as TB-500 is not the full-length thymosin beta-4 that produced almost all the efficacy data, so we label every finding by the molecule it actually used. We grade each finding as confirmed, preclinical, or an outright gap, and we keep the honest gaps — zero completed controlled fragment trials, no validated human half-life, and a genuine tumor and angiogenesis safety signal — in plain sight beside the repair findings, never buried.

We lead with what was measured and we attribute it to a numbered citation. We do not recommend doses for humans; where a dose appears, it is described as administered to a species in a study. We do not name vendors, clinics, or providers, and we do not describe ways to obtain any restricted substance. Regulatory facts are stated present-tense and cited to FDA, with no future agency action presented as decided.

## What this site is not

This is not medical or legal advice, not a treatment service, and not an offer to sell or supply anything. We do not consult, prescribe, diagnose, or dispense. We have no physical location, no clinical staff, and no commercial position in any compound.

What we offer is narrower and, we think, more useful: a precise, cited reading of what the TB-500 and thymosin beta-4 literature establishes, what it only suggests, and where it is simply silent — kept current as new studies land, and honest about the line between the fragment and the protein. If you take one thing from this site, take that line.

---

A fiduciary-grade reading of the TB-500 and thymosin beta-4 record — each finding weighed against its own study and graded for evidence, the fragment-versus-protein line drawn in plain sight, with no clinic, pharmacy, or prescription behind the desk and nothing here dispensed or for sale.